Skip to main
LONA

LeonaBio Inc (LONA) Stock Forecast & Price Target

LeonaBio Inc (LONA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LeonaBio is making significant progress in their pipeline development, with a focus on their lead drug candidates lasofoxifene and ATH-1105. Their rational development strategy supports the potential for lasofoxifene to become a leading treatment in the 2L ER+/HER2- metastatic breast cancer market and address the high unmet need for treatment-resistant breast cancer and ALS. With a well-funded financial position and a strong focus on commercial readiness, LeonaBio is strategically positioned for success in the biopharmaceutical industry.

Bears say

LeonaBio is a clinical-stage biopharmaceutical company with potential in its lead drug candidates lasofoxifene and ATH-1105, which have shown promising results in addressing high unmet medical needs in metastatic breast cancer and ALS, respectively. However, despite positive Phase 2 data for lasofoxifene and a strong pipeline of small-molecule candidates, the company faces significant risks in its early stages of development and will likely need to raise additional capital to support its operations. Therefore, from a financial standpoint, LeonaBio's negative outlook is driven by its lack of current revenue, high R&D expenses, and potential future financing needs.

LeonaBio Inc (LONA) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeonaBio Inc (LONA) Forecast

Analysts have given LeonaBio Inc (LONA) a Buy based on their latest research and market trends.

According to 3 analysts, LeonaBio Inc (LONA) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeonaBio Inc (LONA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.